American Journal of Respiratory and Critical Care Medicine · 2011 · 521 citations · 41 references
MedicinePathobiologyPathologyCell SignalingCellular PathologyMolecular PathologyAntifibrotic TherapyExtracellular MatrixFibrosisGrowth Factor SignalingInterstitial Lung DiseasePulmonary PathologyFibroblast-to-myofibroblast TransitionFibrosis ModulationFibrotic ChangeLung FibrosisMyofibroblast DifferentiationPulmonary Fibrosis ProgressionTransforming Growth Factor Beta RegulationTransforming Growth Factor-beta Signaling
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a chronic dysregulated response to alveolar epithelial injury with differentiation of epithelial cells and fibroblasts into matrix-secreting myofibroblasts resulting in lung scaring. The prognosis is poor and there are no effective therapies or reliable biomarkers. Galectin-3 is a β-galactoside binding lectin that is highly expressed in fibrotic tissue of diverse etiologies. OBJECTIVES: To examine the role of galectin-3 in pulmonary fibrosis. METHODS: We used genetic deletion and pharmacologic inhibition in well-characterized murine models of lung fibrosis. Further mechanistic studies were performed in vitro and on samples from patients with IPF. MEASUREMENTS AND MAIN RESULTS: Transforming growth factor (TGF)-β and bleomycin-induced lung fibrosis was dramatically reduced in mice deficient in galectin-3, manifest by reduced TGF-β1-induced EMT and myofibroblast activation and collagen production. Galectin-3 reduced phosphorylation and nuclear translocation of β-catenin but had no effect on Smad2/3 phosphorylation. A novel inhibitor of galectin-3, TD139, blocked TGF-β-induced β-catenin activation in vitro and in vivo and attenuated the late-stage progression of lung fibrosis after bleomycin. There was increased expression of galectin-3 in the bronchoalveolar lavage fluid and serum from patients with stable IPF compared with nonspecific interstitial pneumonitis and controls, which rose sharply during an acute exacerbation suggesting that galectin-3 may be a marker of active fibrosis in IPF and that strategies that block galectin-3 may be effective in treating acute fibrotic exacerbations of IPF. CONCLUSIONS: This study identifies galectin-3 as an important regulator of lung fibrosis and provides a proof of principle for galectin-3 inhibition as a potential novel therapeutic strategy for IPF.
41
U. Klinge, Joon-Keun Park, B. Klosterhalfen · Pathobiology · 2013 · 1.8K citations · Full text
Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Richard Bucala, Lori Spiegel, Jason Chesney et al. · Molecular Medicine · 1994 · 1.3K citations · Full text
Kevin K. Kim, Matthias C. Kugler, Paul J. Wolters et al. · Proceedings of the National Academy of Sciences · 2006 · 1.2K citations · Full text